Objective In view of the emergence of resistant strain, even under combination therapy,the search for new active drugs, preferably with a new mechanism of action likeAzodicarbonamide, is of the greatest importance from the public health point ofview. Moreover, due to the costs of such combination therapies, these drugsare not available for the majority of patients and for the populations mostconcerned in the countries in development. The goal of the RTD will be toconduct a Phase II study with Azodicarbonamide following the recommendations ofthe expêrts of the European Community. Based on the optimum dose derived from the Phase II a study, a European study will be conducted in a sufficient numberof HIV infected patients from European clinical centers (Three of them havealready signed an agreement). The economical, ethical and social problemconcerning a new drug in AIDS are reviewed. Fields of science medical and health scienceshealth sciencespublic healthmedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV Programme(s) FP4-BIOMED 2 - Specific research, technological development and demonstration programme in the field of biomedicine and health, 1994-1998 Topic(s) Data not available Call for proposal Data not available Funding Scheme EAW - Exploratory awards Coordinator Hubriphar SA Address 40,avenue joseph wybran 1070 Bruxelles Belgium See on map EU contribution € 0,00
